Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy

被引:2
|
作者
Xing, Yumeng [1 ,2 ,3 ]
Yang, Jianhui [1 ,2 ]
Peng, Ao [1 ,2 ]
Qian, Yujing [1 ,2 ]
Liu, Yang [4 ]
Pan, Pei [2 ]
Liu, Qi [1 ,2 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Res Ctr Translat Med, Hefei 230032, Peoples R China
[2] Anhui Med Univ, Sch Pharm, Hefei 230032, Peoples R China
[3] Xiamen Univ, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China
[4] Nankai Univ, Coll Chem, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer immunotherapy; immunogenic cell death; lysosomal membrane permeabilization; nanoparticle aggregation; PD-1/PD-L1; blockade; MEMBRANE PERMEABILIZATION; CELL-DEATH;
D O I
10.1002/adma.202412730
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanotechnology has proven its enormous application value in clinical practice. However, current research on nanomedicines mainly focuses on developing nanoparticles as delivery carriers to maximize the bioavailability of therapeutic agents, with little attention on exploring their potential to directly regulate physiological processes. In this study, inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, this work presents a lysosomal-targeting aggregated nanoparticle (LTANP) for cancer treatment. By rationally engineering surface composition, properties, and interparticle interactions, LTANP achieves efficient tumor accumulation and selective targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately inducing lysosomal membrane permeabilization (LMP) of cancer cells. Further analysis shows that nanoparticle aggregation-mediated LMP can effectively trigger immunogenic cell death (ICD) by impairing autophagy-lysosome pathway, evoking robust antitumor immune responses and reversing tumor immunogenicity from "cold" to "hot" in a melanoma model. Additionally, LTANP can combine with clinically approved programmed death ligand-1 (PD-L1) antibodies to further unleash T cell-mediated antitumor immunity, significantly enhancing antitumor performance, inhibiting tumor recurrence and metastasis. This work demonstrates the potential of rationally engineered nanostructures in directly combating cancer and provides novel insights for the development of advanced nanoparticle-based cancer treatment. Inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, a lysosomal-targeting aggregated nanoparticle (LTANP) is synthesized for cancer treatment. By rationally engineering surface properties and interparticle interactions, LTANP enables targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately selectively inducing lysosomal membrane permeabilization and immunogenic cell death of cancer cells. image
引用
收藏
页数:17
相关论文
共 50 条
  • [21] The Janus Face of Tumor Microenvironment Targeted by Immunotherapy
    Buoncervello, Maria
    Gabriele, Lucia
    Toschi, Elena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
  • [22] Smart Nanoparticle-Based Platforms for Regulating Tumor Microenvironment and Cancer Immunotherapy
    Cheng, Ruoyu
    Santos, Helder A.
    ADVANCED HEALTHCARE MATERIALS, 2023, 12 (08)
  • [23] Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
    Li, Ying
    Xiang, Shuai
    Pan, Wenjun
    Wang, Jing
    Zhan, Hanxiang
    Liu, Shanglong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
    Damien Maggiorani
    Oanh Le
    Véronique Lisi
    Séverine Landais
    Gaël Moquin-Beaudry
    Vincent Philippe Lavallée
    Hélène Decaluwe
    Christian Beauséjour
    Nature Communications, 15
  • [25] The immunosuppressive tumor microenvironment (TME) in nasopharyngeal carcinoma: implications for immunotherapy
    Duffield, Amy S.
    Ascierto, Maria Libera
    Anders, Robert A.
    Taube, Janis M.
    McMiller, Tracee L.
    Engle, Elizabeth L.
    Meeker, Alan K.
    Berger, Alan E.
    Pardoll, Drew M.
    Ambinder, Richard F.
    Topalian, Suzanne L.
    CANCER RESEARCH, 2018, 78 (13)
  • [26] Eliciting an Immunostimulatory Tumor Microenvironment to Enhance the Antitumor Efficacy by Targeted Cancer Immunotherapy
    Zhang, Ya-Xuan
    Zhang, Jun-Jie
    Wang, Wei
    Guo, Xiao-Ying
    Hou, Li-Shuang
    Zhang, Tang-Rui
    Wang, Bao-Long
    Kou, Fang
    Huan, Meng-Lei
    He, Wei
    Zhou, Si-Yuan
    Zhang, Bang-Le
    ADVANCED THERAPEUTICS, 2022, 5 (09)
  • [27] Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
    Maggiorani, Damien
    Le, Oanh
    Lisi, Veronique
    Landais, Severine
    Moquin-Beaudry, Gael
    Lavallee, Vincent Philippe
    Decaluwe, Helene
    Beausejour, Christian
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [28] Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
    Jin, Yuzhi
    Huang, Yangyue
    Ren, Hui
    Huang, Huanhuan
    Lai, Chunyu
    Wang, Wenjun
    Tong, Zhou
    Zhang, Hangyu
    Wu, Wei
    Liu, Chuan
    Bao, Xuanwen
    Fang, Weijia
    Li, Hongjun
    Zhao, Peng
    Dai, Xiaomeng
    BIOMATERIALS, 2024, 305
  • [29] Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
    Otegui, Nerea
    Houry, Maeva
    Arozarena, Imanol
    Serrano, Diego
    Redin, Esther
    Exposito, Francisco
    Leon, Sergio
    Valencia, Karmele
    Montuenga, Luis
    Calvo, Alfonso
    CANCERS, 2023, 15 (12)
  • [30] Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy
    Hakemi, Mazdak Ganjalikhani
    Demirel, Guelderen Yanikkaya
    Li, Yangqiu
    Jayakumar, Nair
    FRONTIERS IN IMMUNOLOGY, 2023, 14